Abstract views: 60 / PDF downloads: 249


  • Mustafa Cellat Department of Physiology, Faculty of Veterinary Medicine, Hatay Mustafa Kemal University, Hatay, Turkey
  • Ares Alizade Department of Pharmacology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey
  • Halil Mahir Kaplan Department of Pharmacology, Faculty of Medicine, Çukurova University, Adana, Turkey
  • Gülşah Evyapan Department of Medical Biology and Genetics, Faculty of Medicine, Cukurova University, Adana, Turkey
  • Memet Güvenç Department of Physiology, Faculty of Veterinary Medicine, Hatay Mustafa Kemal University, Hatay, Turkey


Cucurbitacin, Geldanamycin, colon cancer, apoptosis, synergy


Colon cancer is one of the most common cancers observed in men and women in the world, today in many countries after cardiovascular diseases; it is second leading cause of death. In this the study we aimed to investigate the effects of use of Cucurbitacin I and together with Geldanamycin (GA) which have apoptotic and anti-proliferativeeffects on HT29. Cells were treated with GA, CU and GA+CU. Effect of GA, CU on cell viabilitywere demonstrated by MTT assay and activities of bax, caspase-3, bcl-2, GRP78, wee1, AIF and GAAD153 were performedwith ELISA method after 48 hour treatment. Our study showed that the combined use of GA and CU significantly reduced cell viability of colon cells. Also, the same dose of GA and CU used together increased the expression of proapoptotic proteins and decreased anti-apoptotic proteins more than their effects alone. As aconclusion, our study showed that GA and CU synergistically induce apoptosis on humancolon cancer.


Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (2002): Cell junctions. In Molecular Biology of the Cell, 4th edition, Garland Science.

Haydaroğlu, A., Bölükbaşı, Y., Özsaran, Z. (2007): Ege Üniversitesi'nde kanser Kayıt analizleri: 34134 Olgunun değerlendirmesi. Türk Onkoloji Dergisi 22(1): 22-28.

Boring, C. C., Squires, T. S. (1993): Tong T. Cancer statistics, 1993. Ca Cancer J Clin 43: 7-26.

Eser, S. Y., Karakılınç, H. (2007): Türkiye’de kanser insidansı. Türkiye’de kanser kontrolu. Edit Tuncer M. 17-45.

Dellabona, P., Moro, M., Crosti, M. C., Casorati, G., Corti, A. (1999): Vascular attack and immunotherapy: a ‘two hits’ approach to improve biological treatment of cancer. Gene Therapy 6(2): 153-154.

Aktaş, S. H. (2010): Kemoterapinin kolon kanseri, meme kanseri ve mide kanserinde VEGF düzeylerine etkisinin in vivo ve in vitro incelemesi. (Master’s thesis), Ankara University, Ankara, Turkey.

Lee, C. C., Houghton, P. (2005): Cytotoxicity of plants from Malaysia and Thailand used traditionally to treat cancer. Journal of ethnopharmacology 100(3): 237-243.

Efferth, T., Kahl, S., Paulus, K., Adams, M., Rauh, R., Boechzelt H., Hao, X., Kaina B., Bauer, R. (2008): Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materiamedica with activity against tumor cells. Molecular Cancer Therapeutics 7(1): 152-161.

Ekici, M., Satilmiş, A., Ay, Y. D., Dülger, B., Yer, H. M. (1998): Ecballium elaterium (L.) meyvelerinin sinüzite karşi kullanimi. Ekoloji 27: 24-25.

Chen, J. C., Chiu, M. H., Nie, R. L., Cordell, G. A., Qiu, S. X. (2005): Cucurbitacins and cucurbitane glycosides: structures and biological activities. Natural Product Reports 22(3): 386-399.

Baytop, T. (1963): Tibbi ve Zehirli Bitkiler. Ismail Akgün Matbaasi, 119. İstanbul University, Faculty of Pharmacy, İstanbul, Turkey.

Baytop, T. (1984): Türkiye’de Bitkilerile Tedavi (Treatment with Plants in Turkey). Istanbul Universitesi Eczacılık Fakültesi Yayınları, No: 40, İstanbul, Türkiye.

Atasü, E., Cihangir, V. (1985): Ecballium elaterium L. Bitkisinin FarmakognozideYeri. Pharmacia-JTPA 25(55): 391-395.

Lavie, D., Szinai, S. (1958): The Constituents of Ecballium elaterium L. II. α-Elaterin1, 2. Journal of the American Chemical Society 80(3): 707-710.

Baykut, M., Biran, M., Okçuoğlu, N. (1979): Some Investigations in the Properties of Ecballiumelaterium and its Constituents. Chimica ActaTurcica 7: 57-85.

Roa, M.M., Meshulam, H., Lavie, D. (1974): Constituents of Ecballium elaterium XXIII: Cucurbitacins and hexanorcucurbitacin. J Chem Soc. 22: 2252-6.

Peters, R. R., Krepsky, P. B., Siqueira-Junior, J. M., da SilvaRocha, J. C., Bezerra, M. M., de Albuquerque Ribeiro, R., Brum-Fernandes, A.J., Farias, M.R., da Rocha, F.A.C., Ribeiro-do-Valle, R. M. (2003): Nitricoxide and cyclooxygenase mayparticipate in the analgesic and anti-inflammatory effect of the cucurbitacins fraction from Wilbrandiae bracteata. Life Sciences 73(17): 2185-2197.

Lee, K. H. (2010):Discovery and development of naturalproduct-derived chemotherapeutic agents based on a medicinal chemistry approach. Journal of Natural Products 73(3): 500-516.

Lee, D. H., Iwanski, G. B., Thoennissen, N. H. (2010): Cucurbitacin: ancient compounds hedding new light on cancer treatment. The Scientific World Journal 10: 413-418.

Belkin, M., Fitzgerald, D. B., Cogan, G. W. (1952): Tumor-damagingcapacity of plantmaterials. I. Plantsused as cathartics. J NatlCancerInst. 13(1): 139-155.

Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, Miller PE, Pollalk VA, Savage DM, Sloan DE, Pustilnik LR, Moyer MP. (1995): ErbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, andstructure-activityrelationships. J MedChem 38(19):3806–12.

Li J, Buchner J. (2013): Structure function and regulation of the hsp90 machinery. Biomedical Journal 36:106-117. DOI: 10.4103/2319-4170.113230.

Amraiz D, Zaidi NSS, Fatima M. (2017): Antiviralevaluation of an Hsp90 inhibitor, gedunin, againstdenguevirus. Trop J PharmRes 16:997–1004.

Hao XU, Liu G, Gu H, Wang J, Li Y. (2020): Glutamine protects intestine against ischemia-reperfusion injury by all eviating endoplasmic reticulum stress induced apoptosis in rats. ActaCirBras. 35(1):e202000104.

Dat P. Ha, Yuan-LiTsai, Amy S. Lee. (2021): Suppression of ER-stressinduction of GRP78 as an anti-neoplastic mechanism of the cardiac glycoside Lanatoside C in pancreatic cancer. Neoplasia Volume 23: pp. 1213–1226.

Matheson CJ, Backos DS, Reigan P. (2016): Targeting WEE1 kinase in cancer. Trends Pharmacol Sci. 37(10):872-881.

Vahsen, N., Candé, C., Brière, J. J., Bénit, P., Joza, N., Larochette, N., ... & Kroemer, G. (2004): AIF deficiency compromises oxidative phosphorylation. The EMBO Journal 23(23): 4679-4689.

Basu, A. (2021): The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy. Pharmacology & Therapeutics 107943.

Boatright, Kelly M., and Guy S. Salvesen. (2003): "Mechanisms of caspase activation." Current Opinion in Cell Biology 15.6: 725-731.

Knudson, C. M., & Korsmeyer, S. J. (1997): Bcl-2 and Bax function independently to regulate cell death. Nature Genetics 16(4), 358-363.




How to Cite

Cellat, M., Alizade, A., Kaplan, H. M., Evyapan, G., & Güvenç, M. (2022). INVESTIGATION OF SYNERGISTIC EFFECT OF GELDANAMYCIN AND CUCURBITACIN ON HUMAN COLON CANCER. Journal of Applied Biological Sciences, 16(2), 248–256. Retrieved from




Most read articles by the same author(s)